echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 300 million yuan transfer of four pharmaceutical companies no one asked, listed pharmaceutical companies to sell assets into the wind behind the logic?

    300 million yuan transfer of four pharmaceutical companies no one asked, listed pharmaceutical companies to sell assets into the wind behind the logic?

    • Last Update: 2020-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 9th, the shares of four subsidiaries of Laimei Pharmaceuticals were once again listed on the Chongqing Stock Exchange for transfer.
    this is the 8th time that Lemex Pharmaceuticals has transferred its stake in the four subsidiaries, after seven previous transfers were unsuccessful.
    The underlying shares transferred are 100% of Hunan Kangyuan Pharmaceutical Co., Ltd., with a transfer base price of 200 million yuan, Sichuan Yanzheng Pharmaceutical Co., Ltd. with a 100% stake and a transfer base price of 110 million yuan, Chongqing Laimei Health Industry Co., Ltd. with a 60% stake and a transfer base price of 0.001 million yuan, and Chongqing Laiyuan Chinese Medicine tablet Co., Ltd. with a transfer base price of 12.55 million yuan.
    first half of 2020, operating income in the first half of this year was 598 million yuan, down 24.0 percent from a year earlier, while net profit attributable to the company was 8.1 million yuan, down 115 percent from a year earlier, according to the company's first-half results.
    of the four subsidiaries listed for the transfer, Sichuan Yanzheng's net profit was 2.63 million yuan, Hunan Kangyuan's loss was 17.41 million yuan, Laimei Health's net profit was 1.48 million yuan, and Lai's loss was 1.94 million yuan.
    Pharmaceuticals said the continued public disposal of the underlying stake is the company's need to accelerate its focus on the development of the main industry and avoid competition with controlling shareholders.
    the sharp increase in performance pressure pharmaceutical companies to sell assets to slim down pharmaceutical companies "slim down" is not an example.
    affected by the epidemic and policies, drug companies will generally see a decline in performance in 2020.
    MNC, johnson, Pfizer and Bayer, all fell in varying degrees.
    seems to be in a more difficult position than multinational pharmaceutical companies.
    more than half of pharmaceutical companies reported negative revenue or profit growth, according to the company's revenue figures, which have been disclosed for the 2020 half year.
    , pharmaceutical companies have started to "sell and sell", through the sale of assets, equity and even technology and product transfer, in order to focus on the main industry, in-house funds, seeking development is not difficult to understand.
    According to incomplete statistics, Tai'anTang, Dong'a gum, Northeast Pharmaceuticals, Kangmei Pharmaceuticals, Beida Pharmaceuticals, People's Fu Pharmaceuticals, Tianshili and many other well-known pharmaceutical companies are selling assets or "slimming down" in different forms, in order to speed up the flow of funds, improve the efficiency of asset use.
    August 27, Comey Pharmaceuticals announced revenue of 2.517 billion yuan, down 69.05 percent year-on-year, and a net loss of 1.424 billion yuan, compared with a profit of 85.5 million yuan a year earlier.
    , Kangmei Pharmaceuticals said that the reporting period of the company focused on the main business, adjust business strategy, affected by the outbreak, revenue decreased year-on-year.
    announcement also pointed out that its wholly-owned subsidiary Kangmei Health Industry Investment Co., Ltd. intends to sell the two state-owned construction land use rights and their above- and underground buildings and/or construction projects located in the AH040248 block of Zhangzhou A District, Haizhu District, Guangzhou City, and the cross-municipal road link (10)-2 of the Haizhu District of Guangzhou City.
    Pharmaceuticals said the move was aimed at further incussing assets and focusing on the main business.
    because of performance losses seriously choose to sell the industry is also Dong A gum.
    August 26, Dong'a Gum released its semi-annual report showing that the company's first-half operating income was RMB1,095 million, down 42.06 percent from RMB1.89 billion a year earlier, while the net profit attributable to shareholders of listed companies was RMB84.02 million, down 143.54 percent from a year earlier.
    the same day that the results were announced, Dong A gum began a "slimming" program, announcing the transfer of its 25% stake in China Resources Onde Biopharmaceutical Co., Ltd. to China Resources Biopharmaceuticals.
    the related transaction has little impact on the company's overall earnings, and is able to recover equity investment funds of RMB74.408425 million, increasing the company's cash flow.
    fu medicine is also for performance to slim down the representative.
    August 21, the company reported half-yearly operating income of RMB9,656 million, down 8.23% from a year earlier, and net profit attributable to shareholders of listed companies was RMB392 million, up 16.56% from a year earlier.
    August 5, the company signed a contract with Chongqing Pharmaceuticals to transfer a 70% stake in Sichuan People's Fu Pharmaceuticals to Chongqing Pharmaceuticals for 362 million yuan.
    the company had previously sold its man, Fu Zhongxiang Medical Management Co., Ltd., for $967 million.
    according to People's Fu Pharmaceuticals, this move on the one hand, the divestiture of non-core pharmaceutical assets, continue to optimize the business, capital structure, on the other hand, adhere to the focus of resources to develop established professional sub-areas to achieve business focus.
    Haizheng Pharmaceuticals is also selling assets through the industry.
    incomplete statistics, from the beginning of 2019 to the beginning of 2010, Haizheng Pharmaceuticals returned 3,771 million yuan through the sale of assets.
    August 18, Haizheng Pharmaceuticals released its semi-annual report showing that first-half operating income was 5.31 billion yuan, and net profit attributable to shareholders of listed companies reached 240 million yuan, up 357.31 percent year-on-year.
    to live assets and focus on core business, has become the choice of more and more pharmaceutical companies.
    August 21, Beda Pharmaceuticals announced that it would sell a 100% stake in Zhejiang Bayda Pharmaceutical Technology Co., Ltd. for about 251 million yuan in order to accelerate the withdrawal of funds, replenish cash flow and help new drug research and development.
    August 28, Yan'an Bikang announced its proposed transfer of the Jia'an Information Center project under construction at a proposed asset transfer price of 252 million yuan, and the transfer of the land-use rights of Xinyi Smart Health Town and its seat at a transfer price of not less than RMB1.5 billion.
    Yan'an Bikang said the aim was to improve the efficiency of the company's asset use and optimize the company's asset structure.
    face of the epidemic black swan, pharmaceutical companies may have encountered cash flow difficulties, pharmaceutical companies are gradually moving from expansion-style "buy and buy" to naturalization "sell and sell" in search of further development.
    Transfer of Products and Technologies Focus on core business In addition to the sale of equity or assets for the purpose of focusing on the core business, improving the efficiency of asset use and optimizing the company's asset structure, there are not a few direct transfers of technology or product approvals and optimization of the enterprise product structure.
    industry insiders revealed that, with the State Health Insurance Administration previously clear Chinese medicine drink tablets, Chinese medicine formula particles, chinese medicine exclusive varieties are not included in the collection, the current transfer of Chinese traditional medicine approval has become a new wind.
    June 15, Fangsheng Pharmaceuticals announced that its controlling subsidiary Xiangya Pharmaceuticals commissioned the Hunan Provincial Stock Exchange to organize the transfer of "gastric healing particles" drug production technology.
    , FangSheng Pharmaceuticals said it was unable to confirm the specific amount of research and development investment due to the earlier time to obtain the batch.
    2017-2019, sales of gastric particles were RMB1.942 million, RMB3.1162 million and RMB1.8807 million, respectively, accounting for 2.29%, 3.07% and 2.03% of Fangsheng Pharmaceutical's current revenue.
    Fangsheng Pharmaceuticals said that the transfer of the product will optimize the company's product structure, but also to promote the company and subsidiaries to better implement the "concentration of core resources to build large products" marketing strategy, focus on doing a good job of gastric choice capsule type market development, conducive to its long-term development.
    with the MAH system to unlock drug approval transactions, pharmaceutical companies in accordance with their own conditions for product transfer, restructuring or change their product marketing model.
    July 3, KYU Pharmaceuticals announced its change of clinical trial bid and patent transfer announcement, the announcement shows that KYU pharmaceutical transfer to Sun Ascending (Zhangzhou) left hydroxyphenol capsule technology and related intellectual property rights, LSP capsule is the new cough phlegm compound preparation, intended to be used to treat cough, cough sputum caused by acute and chronic upper respiratory tract infection.
    said the move is conducive to the company's rational distribution of advantageous resources, focusing on key product research and development and sales, in line with the company's long-term development interests.
    Is not unique, on July 24, Shuangcheng Pharmaceuticals intends to grant Hainan Zhong and Pharmaceutical Co., Ltd. the right to own specific intellectual property rights and production technologies related to ideba peptide injections in designated areas for RMB28 million.
    understand that Shuangcheng Pharmaceuticals has specific intellectual property rights related to edide injections, and in January 2019 submitted a drug market license registration application.
    , pharmaceutical companies are moving towards a high concentration, whether it's the sale of equity assets or the transfer of product technology.
    by selling non-core assets to "slim down" and focus on strong business, it will help pharmaceutical companies to further incuss assets, optimize resource allocation, focus on core business, control operational risks, and improve management efficiency.
    With the deepening of medical reform, consistent evaluation, volume procurement and other policies, listed pharmaceutical companies to open the naturalization action, the extension of extensive expansion of mergers and acquisitions development, focusing on strong profitability, development potential of the main industry, has become more and more pharmaceutical companies in the process of strategic transformation of the inevitable choice.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.